Joseph Ehrenfelt v. Janssen Pharmaceuticals

Court of Appeals for the Sixth Circuit·Decided June 11, 2018·No. 17-5292·Unpublished

Opinion

NOT RECOMMENDED FOR PUBLICATION No. 17-5292

UNITED STATES COURT OF APPEALS FOR THE SIXTH CIRCUIT

JOSEPH W. EHRENFELT, ) FILED ) Jun 11, 2018 Plaintiff-Appellant, ) DEBORAH S. HUNT, Clerk )

v. )

)

JANSSEN PHARMACEUTICALS, INC., aka ) ON APPEAL FROM THE Ortho-McNeil-Janssen Pharmaceuticals, Inc., aka ) UNITED STATES DISTRICT Ortho-McNeil Pharmaceutical Products, Inc.; ) COURT FOR THE WESTERN JANSSEN, L.P., fka Janssen Pharmaceutical ) DISTRICT OF TENNESSEE Products, L.P.; JOHNSON & JOHNSON; JANSSEN ) RESEARCH & DEVELOPMENT LLC, fka Johnson ) OPINION & Johnson Pharmaceutical Research & ) Development, LLC; JOHN DOES, 1-50 Inclusive, )

)

Defendants-Appellees. )

BEFORE: GIBBONS, STRANCH, and BUSH, Circuit Judges.

JANE B. STRANCH, Circuit Judge. Plaintiff Joseph Ehrenfelt brings this products liability suit against various divisions of Janssen Pharmaceuticals and Johnson & Johnson, the manufacturers and distributers of the drug Risperdal. Ehrenfelt alleges that he developed gynecomastia as a side effect of using Risperdal. Defendants respond that the flexible statute of repose located in the Kansas Product Liability Act, Kan. Stat. Ann. § 60-3303(b), is inapplicable and that the suit is therefore time-barred by operation of Kansas’s general statute of repose, Kan. Stat. Ann. § 60-513(b). The district court agreed and granted summary judgment to Defendants. Because this suit is governed by the products liability statute of repose, we REVERSE.

I. BACKGROUND

Ehrenfelt first took Risperdal for a period of just over eight months beginning in October 1997, while he was a minor living in Kansas. While hospitalized in February 2000, he again took Risperdal for a few weeks. He discontinued his use of Risperdal for several years and then took the drug again from 2004 to 2006.

Ehrenfelt was first diagnosed with gynecomastia at the end of November 2000.

Gynecomastia is the abnormal enlargement of breast tissue in males. See Breast Enlargement in Males, MedlinePlus, https://medlineplus.gov/ency/article/003165.htm (last visited June 8, 2018). The diagnosing doctor believed his gynecomastia was “due to obesity” and stated this in Ehrenfelt’s medical record.

During the years following Ehrenfelt’s initial diagnosis, new information about Risperdal’s side effects became publicly available. The Risperdal label in use when Ehrenfelt began taking the drug indicated only that its “[s]afety and effectiveness in children ha[d] not been established” and that although gynecomastia “ha[d] been reported” among patients, its incidence was “rare,” defined as “occurring in fewer than 1/1000 patients.” In 2006, the Risperdal label was changed to state that, in clinical trials of children and adolescents, gynecomastia was reported in 2.3% of patients. The label, however, continued to denote gynecomastia as a “rare” adverse effect, which was still defined as occurring in fewer than one in one thousand patients.

According to Ehrenfelt, when he was diagnosed with gynecomastia again in August 2014, the nurse told him to research his past medications because one of them could have caused his condition. Ehrenfelt alleges that it was only upon conducting research after his 2014 medical appointment that he learned about the link between Risperdal and gynecomastia.

Ehrenfelt moved from Kansas to Tennessee in 2009, and filed this suit in Shelby County Circuit Court on July 17, 2015 against corporations and individuals involved in developing,

marketing, and distributing Risperdal. Ehrenfelt’s suit included claims for strict products liability, several varieties of negligence, reckless misconduct, breaches of warranty, fraud, and civil conspiracy. Defendants removed the case to federal court on the basis of diversity of citizenship. The district court ultimately granted summary judgment to Defendants on the ground that Ehrenfelt’s claims were time-barred by Kansas’s ten-year general statute of repose, Kan. Stat. Ann. § 60-513(b). Ehrenfelt timely appealed.

II. ANALYSIS

A. Scope and Standard of Review We review a grant of summary judgment—including a grant of summary judgment on the basis of statutory construction—de novo. See Great Am. Ins. Co. v. E.L. Bailey & Co., 841 F.3d 439, 443 (6th Cir. 2016); Chambers v. Ohio Dep’t of Human Servs., 145 F.3d 793, 800–01 (6th Cir. 1998). “Summary judgment is appropriate only when the evidence, taken in the light most favorable to the nonmoving party, establishes that there is no genuine issue as to any material fact and the movant is entitled to judgment as a matter of law.” Great Am. Ins. Co., 841 F.3d at 443 (quoting V&M Star Steel v. Centimark Corp., 678 F.3d 459, 465 (6th Cir. 2012)).

This appeal turns on a discrete, purely legal issue: which of two Kansas statutes of repose controls in a products liability suit where the relevant harm was caused less than ten years after the product was delivered. If the strict ten-year statute of repose in Kan. Stat. Ann. § 60-513(b) governs, then Ehrenfelt’s claim is time-barred. If, however, the more flexible statute of repose in Kan. Stat. Ann. § 60-3303(b) governs, then Ehrenfelt’s claim might still be cognizable, depending on whether his case fits within one or more of the statutory exceptions specified in § 60- 3303(b)(2)(D).

Determining which statute governs here entails an exercise in statutory interpretation.

Kansas state courts, like their federal counterparts, interpret statutes against a backdrop of

established canons. Those canons guide our inquiry. First, we are mindful that “various provisions of an act in pari materia must be construed together in an effort to reconcile the provisions so as to make them consistent, harmonious and sensible. . . . An appellate court’s duty, as far as practicable, is to harmonize different statutory provisions to make them sensible.” Kan. One-Call Sys., Inc. v. State, 274 P.3d 625, 635 (Kan. 2012) (brackets, citations, and internal quotation marks omitted). In so doing, we “should attempt to give effect to every word and clause” in the statute. State ex rel. Arn v. Consumers Coop. Ass’n, 183 P.2d 423, 438 (Kan. 1947). If we are unable to harmonize two statutes, then we apply the “well-settled rule of law that ‘statutes complete in themselves, relating to a specific thing, take precedence over general statutes.’” Harding v. K.C. Wall Prods., Inc., 831 P.2d 958, 963 (Kan. 1992) (quoting Szoboszlay v. Glessner, 664 P.2d 1327, 1331 (Kan. 1983)).

As a federal court interpreting state laws, we look to “the final decisions of that state’s highest court, and if there is no decision directly on point, then we must make an Erie guess to determine how that court, if presented with the issue, would resolve it.” Sutherland v. DCC Litig. Facility, Inc. (In re Dow Corning Corp.), 778 F.3d 545, 548 (6th Cir. 2015) (quoting Conlin v. Mortg. Elec. Registration Sys., Inc., 714 F.3d 355, 358–59 (6th Cir. 2013)). If our sister circuit whose boundaries include the relevant state has ruled on the issue, we “usually defer” to that interpretation “[u]nless the home circuit has ‘disregarded clear signals emanating from the state’s highest court pointing towards a different rule.’” Id. at 548–49 (quoting Abex Corp. v. Md. Cas. Co., 790 F.2d 119, 125 (D.C. Cir. 1986)). This deference serves the important goal of avoiding the creation of “‘the oddity of a split in the circuits over the correct application’ of one state’s law.” Id. at 549 (quoting Abex Corp., 790 F.2d at 125).

B. Interpreting the Kansas Statutes of Repose Our analysis begins with the text of the two statutes of repose at issue. Kan. Stat. Ann.

§ 60-513 provides:

(a) The following actions shall be brought within two years: . . .

(4) An action for injury to the rights of another, not arising on contract, and not herein enumerated. . . .

Free access — add to your briefcase to read the full text and ask questions with AI

Joseph Ehrenfelt v. Janssen Pharmaceuticals, (6th Cir. 2018).

Joseph Ehrenfelt v. Janssen Pharmaceuticals (Joseph Ehrenfelt v. Janssen Pharmaceuticals) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

V & M STAR STEEL v. Centimark Corp.
678 F.3d 459 (Sixth Circuit, 2012)
Les Kepley v. Gerald Lanz
715 F.3d 969 (Sixth Circuit, 2013)
Dimitrios Papas v. Buchwald Capital Advisors, LLC
728 F.3d 567 (Sixth Circuit, 2013)
Baumann v. Excel Industries, Inc.
845 P.2d 65 (Court of Appeals of Kansas, 1993)
Szoboszlay v. Glessner
664 P.2d 1327 (Supreme Court of Kansas, 1983)
Harding v. K.C. Wall Products, Inc.
831 P.2d 958 (Supreme Court of Kansas, 1992)
Speer v. Wheelabrator Corp.
826 F. Supp. 1264 (D. Kansas, 1993)
Kerns Ex Rel. Kerns v. G.A.C., Inc.
875 P.2d 949 (Supreme Court of Kansas, 1994)
Pamela Sutherland v. DCC Litigation Facility, Inc.
778 F.3d 545 (Sixth Circuit, 2015)
Great American Insurance Co. v. E.L. Bailey & Co.
841 F.3d 439 (Sixth Circuit, 2016)
State ex rel. Arn v. Consumers Cooperative Ass'n
183 P.2d 423 (Supreme Court of Kansas, 1947)